ペンシルベニアにおける食道腺癌の臨床試験
ペンシルベニア内の拠点で、食道腺癌に関する15件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC-Heritage Valley Health System Beaver, Beaver
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- 他24件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Christiana Care Health System-Concord Health Center, Chadds Ford
- 他14件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT05677490A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07221149Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Penn State Milton S. Hershey Medical Center, Hershey
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Alliance Cancer Specialists, PC, Bensalem
- Alliance Cancer Specialists, PC, Doylestown
- Alliance Cancer Specialists, PC, Horsham
- 他4件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07392892A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- University of Pennsylania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
被験者募集中
18歳〜89歳 · 全性別 · 2026/09/11更新 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Hershey
- Research Site, Philadelphia
- Research Site, Pittsburgh
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06657144Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- Geisinger Medical Center, Danville
被験者募集中
18歳〜89歳 · 全性別 · 2026/07/01更新 · NCT05530343Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT04114136Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/23更新 · NCT06340711Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT07223424Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/21更新 · NCT03539822ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。